N
Neumora Therapeutics, Inc. (NMRA)
NMS – Real Time Price. Currency in USD
1.90
+0.03 (1.60%)
At close: May 12, 2026, 4:00 PM EDT
1.91
+0.01 (0.53%)
Pre-market: May 13, 2026, 7:52 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
1.90
+0.03 (1.60%)
At close: May 12, 2026, 4:00 PM EDT
1.91
+0.01 (0.53%)
Pre-market: May 13, 2026, 7:52 AM EDT
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company’s preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson’s Disease; NMRA-CK1δ, a casein kinase 1 isoform delta (CK1δ) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Name | Position |
|---|---|
| Dr. Daljit Singh Aurora Pharm.D. | Chief Operationg & Development officer |
| Dr. Joshua Pinto Ph.D. | President |
| Dr. Nicholas Brandon Ph.D. | Chief Scientific Officer |
| Helen Rubinstein | Head of Investor Relations |
| Mr. Jason G. Duncan J.D. | Chief Legal & Administrative Officer |
| Mr. Michael Lee Milligan | CFO & Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | nmra-20260507.htm |
| 2026-05-07 | 10-Q | nmra-20260331.htm |
| 2026-04-17 | DEFA14A | nmra_-_2026_proxy_-_defa.htm |
| 2026-04-17 | DEF 14A | nmra-20260417.htm |
| 2026-03-30 | S-8 | nmra-20260330.htm |
| 2026-03-30 | 10-K | nmra-20251231.htm |
| 2026-02-11 | 8-K | nmra-20260211.htm |
| 2026-01-12 | 8-K | d34054d8k.htm |
| 2026-01-05 | 8-K | d33765d8k.htm |
| 2025-11-21 | 8-K | d873320d8k.htm |
| Mr. Pablo Gersberg | Chief Information Officer |
| Ms. Amy Sullivan | Chief Human Resources Officer |
| Ms. Carol Suh | Co-Founder & Chief Strategy Officer |
| Ms. Lori Houle | Chief Technical Operations & Quality Officer |